A National Cancer Institute-designated Comprehensive Cancer Center

Make an appointment: 800-826-HOPE

Chen, Yuan , Ph.D.

Yuan Chen, Ph.D. Research
Ubiquitin-like Modifications
Our current research interest is in protein modifications by a family of small proteins known as ubiquitin and its homologues. These modifications control life spans, trafficking, assembly and enzymatic activities of cellular proteins, and are important in nearly every aspect of biological functions. We employ a combination of structural, biochemical, molecular and cellular biological methods to understand these processes in cellular regulation and disease pathogenesis. Specific areas of interest are outlined below.

The Role of SUMOylation in Oncogenesis
Post-translational modifications by the small ubiquitin-like modifiers (SUMO) are important in oncogenesis and cellular response to DNA damage. Recent findings indicate that the key oncogenic pathways driven by Myc and KRas are dependent on, or addicted to, SUMOylation. For example, knocking down of the gene encoding the catalytic subunit of the SUMO activating enzyme (SAE), SAE2, has the strongest synthetic lethal interaction with Myc hyperactivation. We are investigating the molecular mechanisms underlying the synthetic lethality of SUMOylation with Myc hyperactivation and KRas mutations. In addition, we are investigating the structure-activity relationship of how the inhibitors interact with the SAE and inhibit its enzymatic activity, and use this information to guide further improvement of the inhibitors. These studies could potentially improve treatment of many cancers, as overexpression of Myc is estimated to contribute to 70 percent of all human cancers, and KRas is also frequently mutated in human cancers.

SUMO Modifications and HIV Replication
SUMO-specific proteases (SENP) regulate post-translational modifications by SUMO through catalyzing the maturation of SUMO precursors and the removal of SUMO from modified proteins. Small molecule inhibitors of SENPs that function in cells would be valuable tools for elucidating the functions of SENPs. We have recently identified a family of small molecule inhibitors of SENPs that inhibit de-SUMOylation activities in cells. Coincidently, these small molecules had been shown to confer anti-HIV activities in a National Cancer Institute antiviral screen, although the cellular targets and the mechanism of inhibition of HIV were unknown. We are investigating the molecular mechanism of how SUMOylation is involved in HIV life cycle. In addition, we are conducting the structure-activity relationship studies of how these inhibitors interact with the SENPs and inhibit their enzymatic activity, and use this information to develop improved inhibitors. Furthermore, we are interested in exploiting this pathway to develop a potential strategy for a cure of HIV by allowing the immune system to target HIV infected cells without producing infectious virus.

NMR-based Metabolomics
Metabolic activity is a reflection of cellular functions. Our laboratory utilizes nuclear magnetic resonance (NMR) spectroscopy as tools for metabolomic studies, that is, global analysis of metabolic activities. Our goal is to provide information on cellular pathways to understand metabolic dysfunctions of cancer cells.

Application of NMR Methods in Drug Discovery
We are collaborating with several other laboratories with expertise in synthetic chemistry, molecular biology and medical oncology to develop new therapeutics for cancer. State-of-the-art NMR methods are employed to provide information on protein-ligand interactions at an atomic resolution; information that is critical for the rational design of new therapeutics.
Representative Publications:
Gold nanoparticles as a platform for creating a multivalent poly-SUMO chain inhibitor that also augments ionizing radiation
YJ Li, AL Perkins, Y Su, Y Ma, L Colson, DA Horne, Y Chen
Proceedings of the National Academy of Sciences 109 (11), 4092-4097, 2012
The intrinsic affinity between E2 and the Cys domain of E1 in ubiquitin-like modifications
J Wang, W Hu, S Cai, B Lee, J Song, Y Chen
Molecular cell 27 (2), 228-237, 2007
Identification of a SUMO-binding motif that recognizes SUMO-modified proteins
Jing Song, Linda K Durrin, Thomas A Wilkinson, Theodore G Krontiris, Yuan Chen
Proceedings of the National Academy of Sciences of the United States of America, 101 (40), 14373-14378, 2004
More publications can be found at:


NMR Facility
Computers and Software
  • Six Linex workstations
  • Two multi-processor servers
Other Shared Equipment
  • Isothermal titration calorimeter
  • Jasco CD instrument
  • Automated Applied Biosystems (AB) Procise Protein Sequencing System for N-terminal Edman degradation
  • A Perkin Applied Biosystems Procise C-terminal sequencer and a Hewlett Packard C-terminal sequencer
  • Dionex AAA Direct amino acid analyzer
  • HPLC systems suitable for narrow-bore and microcapillary chromatography and equipped for detection of peptides at 214 nm as well as variable wavelength fluorescence detection
  • Pharmacia FPLC for protein purification
  • Perkin-Elmer FTIR
  • Hitachi UV/VIS Spectrophotometer
  • Pharmacia BIAcoreTM System
  • PerSeptive Biosystems BioCAD/SPRINT
  • Bio-Rad scanning Densitometer
  • Three Thermo Finnigan LCQ family ion traps (two Classic and one Deca) equipped with electrospray/LC sources.
  • An Applied Biosystems Mariner electrospray (ES) Orthogonal TOF spectrometer
  • Applied Biosystems Voyager DE STR MALDI-TOF spectrometer
  • Scintillation and gamma counters
  • Wallac Micro Beta counter
  • Tomtec 96-well plate harvester

Lab Members and Alumni

Current Lab Members

Sarah Torres
Administrative Analyst
Ramir Vega
Research Associate
Grace Aldana-Masangkay, Ph.D.
Research Fellow
Aileen Alontaga, Ph.D.
Research Fellow
Nigus D Ambaye, Ph.D.
Research Fellow

Chih-Hong Chen, Ph.D.
Research Fellow

Li Du, Ph.D.
Research Fellow
Yifei Li, Ph.D.
Research Fellow

Yi-Jia Li, Ph.D.
Staff Scientist

Andrew Namanja, Ph.D.
NIH Career Development Award (K01) Recipient

Postdoctoral fellows
Yate-Ching Yuan, Ph.D.
Director of the Bioinformatic Core Facility at Beckman Research Institute of City of Hope

Maria Victoria Botuyan, Ph.D.
Staff scientist at Mayo Clinic, MN, USA

Jerry Hu, Ph.D.
Manager, Materials Research Laboratory Spectroscopy Facility, UC Santa Barbara

Donghai Lin, Ph.D.
Professor at Shanghai Institute of Materia Medica, Chinese Academy of Sciences. 

Suhkmann Kim, Ph.D.
Associate Professor at Pusan National University, Korea. 

Sheng Cai, Ph.D.
Director of the NMR laboratory at Marquette University, Wisconsin, USA

Lingyang Zhu, Ph.D.
Senior Scientist, Array BioPharma Inc. Boulder, CO

Thomas Wilkinson, Ph.D.
Staff Scientist, UCLA

Xuanjun Ai, Ph.D.
Postdoctoral fellow with Dr. Charalampos Kalodimos at Rutgers University
Ikenna Madu, Ph.D.
Scientist Kineta, Inc, Seattle, WA
Yang Su, Ph.D.
Beijing, China
Jianghai Wang, Ph.D.
Senior Scientist, BostonBiochem, MA, USA
Graduate students
Ziming Zhang, Ph.D. (2004)
Director of the Nuclear Magnetic Resonance Core, University of South Florida

Jing Song, Ph.D. (2006)
Jing spent two years as a postdoctoral fellow with Professor Timothy Springer at Harvard Medical School, and now is group leader at BioDuro.

Khue Truong, Ph.D. (2012)
Post doctoral fellow at UCLA.

Research technicians
Qin Liu, M.S., Biomolecular NMR Facility manager, Department of Biochemistry, University of Western Ontario, Canada

Candace Seu, Ph.D. student, UC San Diego

Lisa Fukui, M.D/Ph.D. student, University of Illinois at Urbane Champion

Brian Lee, medical student, SUNY Stony Brook

Larry Tong, medical student, University of Nebraska

Steven Wong, medical student, UCLA

Agreement Download

Academic (nonprofit) License Agreement
Please send two signed originals of the license agreement to:
City of Hope
1500 East Duarte Road
Duarte, California 91010
Attn.:  Director, Office of Technology Licensing
Fax: 626-301-8175
With a copy to:
Dr. Yuan Chen
Department of Molecular Medicine
City of Hope
1500 East Duarte Road
Duarte, California 91010
Fax: 626-301-8186
Industry License Agreement
For more information please contact:
Matthew Grunseth, M.B.S.
Technology Licensing Manager
Our Scientists

Our research laboratories are led by the best and brightest minds in scientific research.

Beckman Research Institute of City of Hope is internationally  recognized for its innovative biomedical research.
City of Hope is one of only 41 Comprehensive Cancer Centers in the country, the highest designation awarded by the National Cancer Institute to institutions that lead the way in cancer research, treatment, prevention and professional education.
Learn more about City of Hope's institutional distinctions, breakthrough innovations and collaborations.
Develop new therapies, diagnostics and preventions in the fight against cancer and other life-threatening diseases.
Support Our Research
By giving to City of Hope, you support breakthrough discoveries in laboratory research that translate into lifesaving treatments for patients with cancer and other serious diseases.
  • Eleven years ago, lymphoma patient Christine Pechera began the long road toward a cancer-free life. She had been diagnosed with non-Hodgkin lymphoma and told by doctors elsewhere that her lifespan likely would be measured in months, not years. Refusing to give up, she came to City of Hope for a second opinion. ...
  • Brain surgery is not for the faint of heart. It takes courage, as well as curiosity and compassion. The truly great surgeons also have a desire to find new, and better ways, of healing the brain. Enter Behnam Badie, M.D., chief of neurosurgery at City of Hope. Now a pioneer in brain tumor treatment, Badie enter...
  • Elizabeth Budde, M.D., Ph.D., wants to encourage infighting. She aims to turn the immune system on itself — to the benefit of patients with acute myeloid leukemia, or AML. AML arises when abnormal white blood cells grow out of control, amassing in the bone marrow and interfering with normal blood cell developme...
  • Six, to date; more soon. Outpatient bone marrow transplants, that is. Finding new ways to deliver quality care with the greatest benefit is a priority for a patient-centered institution like City of Hope. For example, not every bone marrow transplant patient needs to check into the hospital for treatment. In fa...
  • The best measure of success in the fight against cancer is in lives saved and families intact, in extra days made special simply because they exist. Yuman Fong, M.D., chair of the Department of Surgery at City of Hope, understands what precedes that special awareness. When cancer strikes, one minute a person ma...
  • In cancer, expertise matters. So do survival rates, patient safety, patient services and many other factors. City of Hope understands this, as does U.S.News & World Report. The magazine’s 2014-2015 list of best hospitals for cancer once again includes City of Hope, ranking the institution 12 out of 900 elig...
  • At 29, Kommah McDowell was a successful young professional engaged to be married to her best friend. She worked in the financial services sector and kick-boxed to keep in shape and to relax. Then came the diagnosis of triple-negative inflammatory breast cancer, a rare and very aggressive form of breast cancer. ...
  • The well-known drug tamoxifen might not always be the best choice for premenopausal women who have undergone treatment for breast cancer and face a heightened risk of recurrence. A new study suggests that the aromatase inhibitor exemestane, or Aromasin, works slightly better than tamoxifen in preventing cancer ...
  • At age 44, Bridget Hanchette, a mother of three from La Crosse, Wisconsin, was diagnosed with grade IV glioblastoma, the most aggressive type of malignant brain tumor. The cancer grows and spreads quickly, making it difficult to treat. Most patients with this diagnosis are not given much hope, but Hanchette’s i...
  • Survival rates for childhood cancer have improved tremendously over the past few decades, but postcancer care hasn’t always kept up. More children than ever are now coping with long-term complications and side effects caused by their disease and treatment — one of those being learning difficulties. A new ...
  • When Sheldon Querido, a retired manufacturer’s representative, was diagnosed with bladder cancer, his doctor told him that he’d need to have his bladder removed – and that he’d have to wear an external urine-collection bag for the rest of his life. “My first response was ‘I donR...
  • To stop smoking, two approaches might be better than one. A new study has found that using the medication varenicline, or Chantix – along with nicotine patches – was more effective than the medicine alone in helping people quit. The study, conducted by Stellanbosch University in Cape Town, South Africa, and pub...
  • John Cloer was three months shy of his third birthday in 2004 when he was diagnosed with acute lymphoblastic leukemia. For the next three and a half years, he received chemotherapy at City of Hope, finally obtaining long-term remission. His parents Bill and Gina, along with John and his younger brother Steve, r...
  • News about the risks or benefits of widespread cancer screening seem to arrive daily – 3D mammography for breast cancer, CT scans for lung cancer, PSA tests for prostate cancer and now pelvic exams for some women’s cancers. Missing in the headlines is a reflection of how cancer detection is evolving. Today’s ca...
  • Adults with sickle cell disease soon may have a new treatment option: bone marrow transplants. Children with sickle cell disease have been treated successfully with transplantation of bone marrow, more officially known as hematopoietic stem cells, from other people. But the procedure has been less successful in...